Ritonavir
Other / unclassified targets CYP2B6, CYP3A4 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (3) | US (FDA) | NORVIR | — | 1997-03-14 – 2005-10-06 | fda.gov ↗ |
| Approved | EU (EMA) | Norvir | — | 1996-08-25 | europa.eu ↗ |
| Approved | US (FDA) | NORVIR | — | 1996-03-01 | fda.gov ↗ |
Trials 472 · started per year
Also used as a comparator or background therapy in 366 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05386433 Background | Jun → Jul 2022 | COVID-19, uremia | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 167 trials | ||||||
| Phase 1 | NCT06084507 Background | May 2023 | COVID-19 | Fujian Akeylink Biotechnology Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05731804 Background | Mar → Dec 2023 | impaired renal function disease | Jiangsu Simcere Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05544786 Comparator | Sep → Nov 2022 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05178654 Background | Feb → Apr 2022 | — | Pfizer | Withdrawn | No outcome recorded |
| Phase 1 | NCT05129475 Background | Nov 2021 → Jan 2022 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05032950 Comparator | Sep → Dec 2021 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05005312 Background | Aug → Dec 2021 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04909853 Background | Jun → Oct 2021 | impaired renal function disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05242926 Background | Oct 2017 → Apr 2018 | cancer | Modra Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 1 | NCT03234036 Background | Aug → Nov 2017 | HIV infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT05084456 Background | Jul 2017 → Feb 2020 | cancer, liver disorder | Modra Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 1 | NCT03150368 Background | May 2017 → May 2018 | neoplasm | Modra Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT03537404 Background | Apr → Jun 2017 | — | R-Pharm | Completed | No outcome recorded |
| Phase 1 | NCT03070470 Comparator | Mar → Jun 2017 | — | Food and Drug Administration (FDA) | Completed | No outcome recorded |
| Phase 1 | NCT02795754 Background | Mar → Dec 2016 | HIV infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02556268 Background | Feb → Dec 2016 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02565888 Comparator | Nov 2015 → Jan 2016 | HIV infectious disease, hepatitis C virus infection | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT02631473 Comparator | Nov 2015 → Nov 2017 | HIV infectious disease | St Stephens Aids Trust | Suspended | No outcome recorded |
| Phase 1 | NCT03019991 Background | Oct → Nov 2015 | — | Ascletis Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02289495 Background | Nov 2014 → Jun 2015 | HIV infectious disease | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT02203461 Comparator | Jul → Oct 2014 | — | Technical University of Munich | Completed | No outcome recorded |
| Phase 1 | NCT02064842 Background | Feb → Apr 2014 | — | Janssen R&D Ireland | Completed | No outcome recorded |
| Phase 1 | NCT02052362 Background | Jan → Feb 2014 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT01759875 Comparator | Jan 2013 → Jan 2014 | — | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT01654211 Background | Jul → Nov 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01592318 Comparator | May → Jun 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01695954 Background | May 2012 → Jan 2013 | HIV infectious disease, hyperlipidemia | NYU Langone Health | Completed | No outcome recorded |
| Phase 1 | NCT01638650 Background | Jan → Jun 2012 | HIV infectious disease | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01392755 Background | Jul → Sep 2011 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01374802 Background | Jun → Jul 2011 | HIV infectious disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01332552 Background | Jan → Apr 2011 | hepatitis C virus infection | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT01209065 Background | Sep → Nov 2010 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT01156389 Comparator | Jul → Aug 2010 | malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 1 | NCT01091649 Comparator | Feb → Apr 2010 | — | Abbott | Completed | No outcome recorded |
| Phase 1 | NCT00833482 Comparator | Sep 2009 → Jul 2010 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00931281 Comparator | Jun → Sep 2009 | hepatitis C virus infection | Abbott | Completed | No outcome recorded |
| Phase 1 | NCT01047995 Comparator | Jun → Dec 2009 | HIV infectious disease | St Stephens Aids Trust | Completed | No outcome recorded |
| Phase 1 | NCT00909311 Comparator | May → Jul 2009 | hepatitis C virus infection | Abbott | Completed | No outcome recorded |
| Phase 1 | NCT00867152 Background | Apr → May 2009 | — | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT00850044 Comparator | Feb → Jul 2009 | hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT00833378 Comparator | Jan → Mar 2009 | hepatitis C virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00817765 Comparator | Jan → Jul 2009 | HIV infectious disease, fungal infectious disease | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00765271 Comparator | May → Oct 2008 | HIV infectious disease | St Stephens Aids Trust | Completed | No outcome recorded |
| Phase 1 | NCT00646776 Comparator | Apr → Aug 2008 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00531999 Comparator | Oct 2007 → Aug 2008 | HIV infectious disease | St Stephens Aids Trust | Completed | No outcome recorded |
| Phase 1 | NCT02253940 Background | Oct → Dec 2006 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00362726 Comparator | Sep → Nov 2006 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00357188 Comparator | Jul → Sep 2006 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00326716 Background | Jun 2006 → Jan 2009 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00357240 Comparator | Jun → Aug 2006 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02253927 Background | May → Aug 2006 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00365339 Comparator | Apr → Jun 2006 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02226991 Background | Apr → Jul 2006 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02248883 Background | Dec 2005 → Mar 2006 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00266058 Comparator | Dec 2005 → Nov 2010 | HIV infectious disease, malaria | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT00162149 Background | Oct 2005 → Jul 2006 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02259868 Background | Jun → Sep 2005 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02256826 Background | Apr → Jun 2005 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00481182 Background | Feb 2005 → ? | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02256774 Background | Oct 2004 → May 2005 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00135434 Background | Sep 2004 → Jun 2005 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02253914 Background | Feb → Dec 2004 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02251171 Background | Aug → Oct 2003 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02245269 Background | Jul → Oct 2003 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02253797 Background | Jul 2003 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00001968 Background | Jan → Nov 2000 | AIDS | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00000822 Background | ? → May 1999 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/212 trials | ||||||
| Phase 1/2 | NCT05779579 Background | Feb → May 2023 | COVID-19 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05369676 Background | May → Aug 2022 | — | Jiangsu Simcere Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT04390152 Comparator | Jan 2020 → Mar 2022 | acute respiratory distress syndrome | BioXcellerator | Terminated | No outcome recorded |
| Phase 1/2 | NCT03836833 Background | Jun → Nov 2019 | HIV infectious disease | Drugs for Neglected Diseases | Unknown | No outcome recorded |
| Phase 1/2 | NCT04391985 Comparator | Mar → Oct 2017 | chronic hepatitis C virus infection | Beni-Suef University | Completed | No outcome recorded |
| Phase 1/2 | NCT04378608 Background | Jan → Sep 2017 | chronic hepatitis C virus infection | Beni-Suef University | Completed | No outcome recorded |
| Phase 1/2 | NCT01668147 Comparator | Aug 2012 → Jun 2016 | drug-induced mental disorder | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT00885495 Comparator | Jan 2009 → Apr 2010 | HIV infectious disease | University of Cincinnati | Completed | No outcome recorded |
| Phase 1/2 | NCT00622206 Comparator | Jan → Apr 2008 | HIV infectious disease | The HIV Netherlands Australia Thailand Research Collaboration | Completed | No outcome recorded |
| Phase 1/2 | NCT00411996 Background | Dec 2006 → Oct 2008 | HIV infectious disease, tuberculosis | The HIV Netherlands Australia Thailand Research Collaboration | Completed | No outcome recorded |
| Phase 1/2 | NCT02229760 Background | Aug 2006 → Sep 2007 | HIV infectious disease | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1/2 | NCT00004578 Comparator | Nov 1997 → Apr 2005 | HIV infectious disease | Abbott | Completed | No outcome recorded |
| Phase 279 trials | ||||||
| Phase 2 | NCT07157007 Comparator | Sep 2025 → Feb 2026 overdue | COVID-19 | Traws Pharma, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06338826 Background | Feb 2025 → Sep 2027 expected | HIV infectious disease | ANRS, Emerging Infectious Diseases | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05595369 Background | Jul 2023 → Aug 2024 | long COVID-19 | Kanecia Obie Zimmerman | Completed | No outcome recorded |
| Phase 2 | NCT06676410 Comparator | Jul 2023 → Dec 2024 overdue | HIV infectious disease | Code Pharma | Recruiting | No outcome recorded |
| Phase 2 | NCT05823896 Comparator | May 2023 → Nov 2024 | COVID-19, long COVID-19, post-infectious syndrome, postural orthostatic tachycardia syndrome | Karolinska Institutet | Completed | No outcome recorded |
| Phase 2 | NCT05668091 Background | Apr 2023 → Apr 2024 | long COVID-19 | Harlan M Krumholz | Completed | No outcome recorded |
| Phase 2 | NCT05545319 Background | Dec 2022 → Sep 2023 | COVID-19, immunodeficiency disease | Pfizer | Withdrawn | No outcome recorded |
| Phase 2 | NCT05576662 Background | Nov 2022 → Aug 2023 | long COVID-19 | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT05567952 Background | Oct 2022 → Sep 2023 | COVID-19 | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT05373446 Background | May → Oct 2022 | COVID-19 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT05041907 Comparator | Sep 2021 → Jan 2027 expected | COVID-19 | University of Oxford | Recruiting | No outcome recorded |
| Phase 2 | NCT04521400 Background | Aug → Sep 2020 | COVID-19 | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT04374539 Comparator | Apr 2020 → Jun 2021 | COVID-19 | Fundacion Clinic per a la Recerca Biomédica | Terminated | No outcome recorded |
| Phase 2 | NCT04343768 Background | Apr 2020 | COVID-19 | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT04276688 Comparator | Feb → Mar 2020 | COVID-19 | The University of Hong Kong | Completed | No outcome recorded |
| Phase 2 | NCT04028388 Background | Jul 2019 → Nov 2021 | castration-resistant prostate carcinoma, metastatic prostate carcinoma | Modra Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03890744 Background | Jan 2019 → Feb 2020 | Her2-receptor negative breast cancer | Modra Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03589040 Background | Sep 2018 → Jun 2019 | HIV infectious disease | Makerere University | Unknown | No outcome recorded |
| Phase 2 | NCT03589027 Background | Aug 2018 → Jun 2019 | HIV infectious disease | Makerere University | Unknown | No outcome recorded |
| Phase 2 | NCT03600714 Background | Aug 2018 → Feb 2020 | hepatitis D virus infection | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 2 | NCT03485846 Background | Nov 2017 → Aug 2018 | chronic hepatitis C virus infection | R-Pharm | Completed | No outcome recorded |
| Phase 2 | NCT02738502 Background | Jul 2016 → Jul 2019 | viral infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 2 | NCT03020004 Background | Jan → Nov 2016 | chronic hepatitis C virus infection | Ascletis Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02336074 Background | Nov 2015 → Nov 2017 | HIV infectious disease | Imperial College London | Completed | No outcome recorded |
| Phase 2 | NCT02527707 Background | Sep 2015 → Aug 2016 | hepatitis D virus infection | Eiger BioPharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03020095 Background | Aug 2015 → Aug 2016 | chronic hepatitis C virus infection | Ascletis Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02511431 Background | Jul 2015 → Feb 2017 | hepatitis D virus infection | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 2 | NCT02386098 Background | Jul 2015 → Jun 2017 | HIV infectious disease | ViiV Healthcare | Terminated | No outcome recorded |
| Phase 2 | NCT02493855 Background | Jun 2015 → Apr 2016 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT02473328 Background | Jun 2015 → Dec 2017 | HIV infectious disease | Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida | Completed | No outcome recorded |
| Phase 2 | NCT02430194 Background | Dec 2014 → Apr 2017 | hepatitis D virus infection | Eiger BioPharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02116660 Comparator | Sep 2014 → Jul 2017 | HIV infectious disease | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT01995071 Background | Nov 2013 → Jun 2015 | chronic hepatitis C virus infection, cirrhosis of liver | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01803074 Background | Apr 2013 → Nov 2014 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 2 | NCT01749150 Background | Apr 2013 → Feb 2015 | chronic hepatitis C virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01724086 Background | Oct 2012 → Sep 2014 | chronic hepatitis C virus infection | Janssen R&D Ireland | Completed | No outcome recorded |
| Phase 2 | NCT01685203 Background | Aug 2012 → Jun 2014 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01672983 Background | Jul 2012 → May 2014 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01628094 Background | Jun 2012 → Nov 2013 | chronic hepatitis C virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01125696 Background | May 2012 → May 2018 | HIV infectious disease, hepatitis B virus infection | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 2 | NCT01483742 Background | Apr 2012 → Sep 2013 | chronic hepatitis C virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01563536 Background | Feb → Apr 2012 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01400412 Background | Jan 2012 → Jun 2014 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 2 | NCT01464827 Background | Oct 2011 → Mar 2013 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01458535 Background | Sep 2011 → May 2013 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01384734 Comparator | Jul 2011 → Feb 2013 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 2 | NCT01656109 Background | Jul 2011 → Feb 2013 | HIV infectious disease | The HIV Netherlands Australia Thailand Research Collaboration | Completed | No outcome recorded |
| Phase 2 | NCT01331850 Background | May 2011 → Jan 2013 | chronic hepatitis C virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01278134 Background | Feb 2011 → Oct 2012 | chronic hepatitis C virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01306617 Background | Feb → Nov 2011 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01254656 Background | Feb 2011 → Apr 2013 | — | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT01220947 Background | Nov 2010 → Dec 2012 | chronic hepatitis C virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01221298 Background | Oct 2010 → May 2011 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT00945282 Background | Oct → Nov 2009 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 2 | NCT00896051 Background | Aug 2009 → Apr 2012 | AIDS | Janssen R&D Ireland | Completed | No outcome recorded |
| Phase 2 | NCT01391013 Background | Jun 2009 → Apr 2011 | HIV infectious disease | Janssen-Cilag S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT00892437 Comparator | May → Dec 2009 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00827112 Background | Mar 2009 → Jul 2010 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 2 | NCT00665847 Background | Nov 2008 → May 2011 | — | Tibotec Pharmaceuticals, Ireland | Completed | No outcome recorded |
| Phase 2 | NCT00768989 Comparator | Nov 2008 → Jan 2010 | HIV infectious disease | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 2 | NCT00764465 Comparator | Oct → Dec 2008 | — | Garden State Infectious Disease Associates, PA | Completed | No outcome recorded |
| Phase 2 | NCT00623597 Background | Jun 2008 → Mar 2010 | HIV infectious disease | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT00654147 Comparator | Apr 2008 → Jan 2012 | HIV infectious disease | Margaret A. Fischl, M.D. | Completed | No outcome recorded |
| Phase 2 | NCT00460382 Background | May 2007 → Mar 2008 | HIV infectious disease | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
| Phase 2 | NCT00445146 Background | Feb 2007 → Mar 2015 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00513513 Background | Sep 2006 → Sep 2007 | HIV infectious disease | Tibotec Pharmaceuticals, Ireland | Terminated | No outcome recorded |
| Phase 2 | NCT00122603 Background | Dec 2005 → Aug 2007 | HIV infectious disease | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
| Phase 2 | NCT00242879 Background | Aug 2005 → Jun 2007 | HIV infectious disease | ViiV Healthcare | Terminated | No outcome recorded |
| Phase 2 | NCT02187107 Background | Jan → Sep 2005 | HIV infectious disease | Tibotec Pharmaceuticals, Ireland | Completed | No outcome recorded |
| Phase 2 | NCT00102778 Background | Dec 2004 → Sep 2007 | HIV infectious disease | ViiV Healthcare | Terminated | No outcome recorded |
| Phase 2 | NCT00257621 Background | Oct 2004 → Jan 2007 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 2 | NCT00084149 Background | Feb 2004 → Jan 2008 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00081588 Background | Nov 2003 → Sep 2005 | HIV infectious disease | Tibotec Pharmaceuticals, Ireland | Completed | No outcome recorded |
| Phase 2 | NCT00052117 Background | Jan 2003 → May 2005 | HIV infectious disease | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00043953 Background | Aug 2002 → ? | HIV infectious disease | Abbott | Completed | No outcome recorded |
| Phase 2 | NCT00006144 Background | Oct 2000 → Apr 2005 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT02238314 Background | Jan 1999 → Aug 2001 | HIV infectious disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT00001058 Background | ? → Jan 1999 | HIV infectious disease, Mycobacterium avium complex disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT02968641 Comparator | ? → Feb 2021 | hepatitis D virus infection | Eiger BioPharmaceuticals | Withdrawn | No outcome recorded |
| Phase 2/310 trials | ||||||
| Phase 2/3 | NCT05656443 Background | Dec 2022 → May 2023 | pneumonia | Fujian Akeylink Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 2/3 | NCT05047601 Background | Sep 2021 → Apr 2022 | COVID-19 | Pfizer | Completed | No outcome recorded |
| Phase 2/3 | NCT04960202 Background | Jul → Dec 2021 | COVID-19 | Pfizer | Completed | No outcome recorded |
| Phase 2/3 | NCT04475120 Comparator | Apr → Jul 2020 | COVID-19 | University of Rome Tor Vergata | Completed | No outcome recorded |
| Phase 2/3 | NCT04331470 Background | Apr 2020 | COVID-19 | Fasa University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2/3 | NCT03362814 Background | Jul 2017 → Dec 2018 | hepatitis C virus infection | Ascletis Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 2/3 | NCT01154673 Background | Nov 2011 → Sep 2014 | — | University of Toronto | Completed | No outcome recorded |
| Phase 2/3 | NCT00834457 Comparator | Jun 2007 → Jul 2009 | Kaposi's sarcoma | Parirenyatwa Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT00038519 Background | Apr 2001 → ? | HIV infectious disease | Abbott | Completed | No outcome recorded |
| Phase 2/3 | NCT00476983 Background | — | — | The HIV Netherlands Australia Thailand Research Collaboration | Withdrawn | No outcome recorded |
| Phase 388 trials | ||||||
| Phase 3 | NCT06747507 Comparator | Sep 2025 → Dec 2026 expected | HIV infectious disease | University of Nairobi | Recruiting | No outcome recorded |
| Phase 3 | NCT05852873 Comparator | May 2023 → Sep 2025 overdue | COVID-19, post-COVID-19 disorder | Haukeland University Hospital | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05271929 Background | Apr 2022 → Jan 2024 | COVID-19 | German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen | Terminated | No outcome recorded |
| Phase 3 | NCT04022967 Background | Sep 2020 → Feb 2025 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Unknown | No outcome recorded |
| Phase 3 | NCT04403100 Comparator | Jun 2020 → Feb 2021 | COVID-19, respiratory tract infectious disorder | Cardresearch | Unknown | No outcome recorded |
| Phase 3 | NCT04364022 Comparator | Apr 2020 → Mar 2021 | — | Calmy Alexandra | Completed | No outcome recorded |
| Phase 3 | NCT04381936 Comparator | Mar 2020 → Sep 2028 expected | pneumonia | University of Oxford | Recruiting | No outcome recorded |
| Phase 3 | NCT03988452 Background | Jul 2019 → Sep 2020 | HIV infectious disease | Makerere University | Unknown | No outcome recorded |
| Phase 3 | NCT03631732 Comparator | Aug 2018 → Aug 2019 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02671383 Comparator | Jun 2016 → May 2018 | HIV infectious disease | Willem Daniel Francois Venter | Completed | No outcome recorded |
| Phase 3 | NCT02616783 Comparator | Dec 2015 → Feb 2018 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02603107 Background | Nov 2015 → May 2017 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02605954 Comparator | Nov 2015 → Jun 2017 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02486133 Background | Jul 2015 → May 2018 | HIV infectious disease | Technical University of Munich | Completed | No outcome recorded |
| Phase 3 | NCT02469246 Background | Jun 2015 → Dec 2017 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02269917 Comparator | Mar 2015 → Feb 2017 | HIV infectious disease | Janssen R&D Ireland | Completed | No outcome recorded |
| Phase 3 | NCT02227238 Comparator | Dec 2014 → Aug 2017 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 3 | NCT02275780 Comparator | Dec 2014 → Sep 2016 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT02247687 Comparator | Dec 2014 → Sep 2015 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Terminated | No outcome recorded |
| Phase 3 | NCT02247401 Comparator | Nov 2014 → Aug 2016 | hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02219672 Comparator | Jul 2014 → Jul 2016 | AIDS | Peking Union Medical College | Unknown | No outcome recorded |
| Phase 3 | NCT02167945 Background | Jun 2014 → May 2021 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02121795 Background | May 2014 → Aug 2015 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02155101 Comparator | May 2014 → Jun 2016 | HIV infectious disease | University of Liverpool | Completed | No outcome recorded |
| Phase 3 | NCT02369965 Background | Feb 2014 → Apr 2018 | AIDS | Frontier Biotechnologies Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01905059 Comparator | Feb 2014 → Apr 2016 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT01966822 Comparator | Jan 2014 → Oct 2015 | HIV infectious disease | Fight AIDS and Infectious Diseases Foundation | Completed | No outcome recorded |
| Phase 3 | NCT01900106 Comparator | Nov 2013 → Dec 2017 | HIV infectious disease | University of Modena and Reggio Emilia | Completed | No outcome recorded |
| Phase 3 | NCT01910402 Comparator | Aug 2013 → Sep 2015 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 3 | NCT01773070 Background | Jun 2013 → Oct 2016 | hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT01815736 Comparator | Mar 2013 → Mar 2015 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01854697 Background | Mar 2013 → Nov 2014 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT01767116 Background | Dec 2012 → Dec 2013 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT01620944 Background | Jul 2012 → Jan 2013 | HIV infectious disease | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 3 | NCT01605084 Background | Jun 2012 → Aug 2014 | HIV infectious disease | Bristol-Myers Squibb | Withdrawn | No outcome recorded |
| Phase 3 | NCT01480713 Background | May 2012 → May 2014 | HIV infectious disease | IrsiCaixa | Completed | No outcome recorded |
| Phase 3 | NCT01448707 Background | Mar 2012 → Jun 2014 | AIDS | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 3 | NCT01516970 Comparator | Nov 2011 → Aug 2013 | HIV infectious disease | Janssen-Cilag GmbH | Completed | No outcome recorded |
| Phase 3 | NCT01475838 Comparator | Nov 2011 → Nov 2013 | AIDS | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01449929 Comparator | Oct 2011 → Apr 2013 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 3 | NCT01345630 Background | Sep 2011 → Aug 2013 | — | ViiV Healthcare | Terminated | No outcome recorded |
| Phase 3 | NCT01335698 Background | May 2011 → Sep 2014 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT01237444 Comparator | Dec 2010 → May 2012 | HIV infectious disease | Pedro Cahn | Completed | No outcome recorded |
| Phase 3 | NCT01252940 Background | Nov 2010 → Jan 2012 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01099579 Background | Oct 2010 → Oct 2012 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT01066962 Background | Aug 2010 → Oct 2013 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT01106586 Comparator | Apr 2010 → Sep 2011 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01033760 Background | Apr 2010 → Jul 2013 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT01108510 Comparator | Apr 2010 → Nov 2011 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00988039 Comparator | Mar 2010 → Jan 2014 | HIV infectious disease | Medical Research Council | Completed | No outcome recorded |
| Phase 3 | NCT00936195 Comparator | Jan 2010 → Jan 2013 | HIV infectious disease, pregnancy disorder | French National Agency for Research on AIDS and Viral Hepatitis | Withdrawn | No outcome recorded |
| Phase 3 | NCT00928187 Comparator | Nov 2009 → Sep 2013 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT00874523 Comparator | Jul 2009 → Jul 2011 | HIV infectious disease | Kirby Institute | Completed | No outcome recorded |
| Phase 3 | NCT00708162 Background | Jul 2008 → Dec 2010 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00727597 Background | Jul 2008 → Aug 2010 | HIV infectious disease | Georgetown University | Completed | No outcome recorded |
| Phase 3 | NCT00427297 Comparator | Sep 2007 → May 2009 | HIV infectious disease | University of Washington | Terminated | No outcome recorded |
| Phase 3 | NCT00517192 Background | Sep 2007 → Sep 2008 | HIV infectious disease | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 3 | NCT00443729 Comparator | May 2007 → Oct 2008 | HIV infectious disease | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 3 | NCT00443703 Comparator | May 2007 → Apr 2009 | HIV infectious disease | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 3 | NCT00454337 Background | May 2007 → Sep 2008 | HIV infectious disease | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
| Phase 3 | NCT01002898 Background | Apr 2007 → Feb 2011 | HIV infectious disease | Bamrasnaradura Infectious Diseases Institute | Completed | No outcome recorded |
| Phase 3 | NCT00421551 Background | Mar 2007 → Jun 2010 | HIV infectious disease | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
| Phase 3 | NCT00447902 Background | Mar 2007 → Oct 2008 | HIV infectious disease | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 3 | NCT00358917 Comparator | Aug 2006 → Nov 2008 | HIV infectious disease | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00234091 Comparator | Apr 2006 → Sep 2011 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT00262522 Comparator | Nov 2005 → Jul 2008 | HIV infectious disease | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00272779 Comparator | Nov 2005 → Jun 2007 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00280969 Background | Sep 2005 → Sep 2009 | HIV infectious disease | International Medical Center of Japan | Completed | No outcome recorded |
| Phase 3 | NCT00258557 Background | Sep 2005 → Jun 2007 | HIV infectious disease | Tibotec Pharmaceuticals, Ireland | Completed | No outcome recorded |
| Phase 3 | NCT00105079 Comparator | Apr 2005 → Aug 2007 | HIV infectious disease | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00110877 Background | Apr 2005 → Jan 2007 | HIV infectious disease | Tibotec Pharmaceuticals, Ireland | Completed | No outcome recorded |
| Phase 3 | NCT00144833 Background | Mar 2005 → ? | — | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 3 | NCT00234910 Background | Jan 2005 → Jun 2007 | HIV infectious disease | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00135395 Comparator | May 2004 → Feb 2006 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00144287 Background | May 2004 → Apr 2006 | HIV infectious disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00085943 Background | May 2004 → ? | HIV infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00135343 Background | Apr 2004 → Oct 2005 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00285883 Background | Apr 2004 → May 2006 | HIV infectious disease | Saint Michael's Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00164736 Comparator | Mar 2004 → Jan 2010 | HIV infectious disease | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 3 | NCT00120393 Comparator | Jan 2004 → May 2006 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00234923 Comparator | Aug 2003 → Feb 2007 | HIV infectious disease | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00144170 Background | Feb 2003 → Oct 2008 | HIV infectious disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00054717 Background | Jan 2003 → Sep 2008 | HIV infectious disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT01003990 Background | Oct 2002 → Feb 2016 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00035932 Comparator | Nov 2001 → Jul 2003 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00296504 Background | Nov 2001 → Oct 2010 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 3 | NCT00038636 Background | Sep 2000 → ? | HIV infectious disease | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00966160 Comparator | Jan 1999 → Dec 2008 | AIDS | University of Cologne | Completed | No outcome recorded |
| Phase 489 trials | ||||||
| Phase 4 | NCT06441955 Comparator | Mar 2024 → Sep 2030 expected | long COVID-19 | Well- Konnect Healthcare Services and Research Firm | Recruiting | No outcome recorded |
| Phase 4 | NCT05697055 Comparator | Jan → May 2023 | COVID-19 | Shandong Provincial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04779047 Comparator | Oct 2020 → Mar 2021 | COVID-19, pneumonia | October 6 University | Unknown | No outcome recorded |
| Phase 4 | NCT04350684 Background | Apr 2020 | COVID-19 | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT04350671 Background | Apr 2020 | COVID-19 | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT04345276 Background | Mar → Apr 2020 | COVID-19 | Huoshenshan Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04286503 Comparator | Feb 2020 → Feb 2021 | COVID-19 | Beijing YouAn Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04291729 Background | Feb → Mar 2020 | COVID-19 | The Ninth Hospital of Nanchang | Completed | No outcome recorded |
| Phase 4 | NCT03017872 Background | Nov 2017 → Nov 2022 | HIV infectious disease | Kirby Institute | Unknown | No outcome recorded |
| Phase 4 | NCT03296930 Comparator | Oct 2017 → Sep 2018 | poisoning | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT02786537 Comparator | Jun 2016 → Jun 2019 | chronic hepatitis C virus infection | University of Florida | Completed | No outcome recorded |
| Phase 4 | NCT02770508 Background | Nov 2015 → Jul 2017 | HIV infectious disease | Fundación Huésped | Completed | No outcome recorded |
| Phase 4 | NCT02198443 Comparator | Jun 2015 → Jul 2016 | HIV infectious disease | Fundacion Clinic per a la Recerca Biomédica | Completed | No outcome recorded |
| Phase 4 | NCT02470650 Comparator | Jun 2015 → Jul 2017 | poisoning | Juan A. Arnaiz | Withdrawn | No outcome recorded |
| Phase 4 | NCT02461745 Comparator | Jun 2015 → May 2017 | chronic hepatitis C virus infection | Kaiser Permanente | Completed | No outcome recorded |
| Phase 4 | NCT02513147 Background | Jun 2015 → Nov 2016 | — | Hospital Universitari Vall d'Hebron Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT01902186 Background | Sep 2014 → Dec 2016 | HIV infectious disease | Giovanni Di Perri | Terminated | No outcome recorded |
| Phase 4 | NCT03133065 Comparator | Sep 2014 → Dec 2016 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT01829802 Background | May 2014 → Oct 2017 | HIV infectious disease | Pedro Cahn | Unknown | No outcome recorded |
| Phase 4 | NCT01599364 Background | Apr 2014 → Apr 2016 | HIV infectious disease | Catholic University of the Sacred Heart | Completed | No outcome recorded |
| Phase 4 | NCT01869634 Comparator | Jun 2013 → Dec 2016 | HIV infectious disease | University of California, Davis | Completed | No outcome recorded |
| Phase 4 | NCT01641367 Background | Feb 2013 → Nov 2016 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 4 | NCT01367236 Background | Jan 2013 → Oct 2015 | HIV infectious disease, cognitive disorder | Imperial College London | Completed | No outcome recorded |
| Phase 4 | NCT01736761 Background | Dec 2012 → Mar 2015 | HIV infectious disease | St Stephens Aids Trust | Completed | No outcome recorded |
| Phase 4 | NCT01691794 Comparator | Nov 2012 → Oct 2014 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 4 | NCT01576731 Comparator | Jul 2012 → Jul 2014 | HIV infectious disease | Hospital Clinic of Barcelona | Completed | No outcome recorded |
| Phase 4 | NCT01637259 Comparator | Jun 2012 → Dec 2015 | HIV infectious disease, proteinuria | Kirby Institute | Completed | No outcome recorded |
| Phase 4 | NCT01533272 Background | Feb 2012 → Jun 2014 | HIV infectious disease | Hospital Clinic of Barcelona | Completed | No outcome recorded |
| Phase 4 | NCT01702090 Background | Feb → Jun 2012 | — | Janssen-Cilag Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT01602822 Background | Feb → May 2012 | HIV infectious disease | Kenneth H. Mayer, MD | Terminated | No outcome recorded |
| Phase 4 | NCT01332227 Background | Oct 2011 → Sep 2013 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 4 | NCT01307488 Background | Sep 2011 → Apr 2014 | HIV infectious disease | Fundacion SEIMC-GESIDA | Completed | No outcome recorded |
| Phase 4 | NCT01351740 Comparator | Jul 2011 → Jan 2015 | HIV infectious disease | University of British Columbia | Completed | No outcome recorded |
| Phase 4 | NCT01367210 Background | Jun 2011 → Jun 2015 | HIV infectious disease | Catholic University of the Sacred Heart | Terminated | No outcome recorded |
| Phase 4 | NCT01192035 Comparator | May 2011 → Sep 2014 | — | University of Aarhus | Completed | No outcome recorded |
| Phase 4 | NCT01159223 Background | May 2011 → Dec 2014 | HIV infectious disease | The HIV Netherlands Australia Thailand Research Collaboration | Completed | No outcome recorded |
| Phase 4 | NCT01274780 Background | May 2011 → May 2013 | — | Juan A. Arnaiz | Completed | No outcome recorded |
| Phase 4 | NCT01232127 Background | Feb → Jun 2011 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 4 | NCT01234116 Comparator | Feb 2011 → May 2013 | HIV infectious disease | Henry Ford Health System | Completed | No outcome recorded |
| Phase 4 | NCT01189695 Background | Dec 2010 → Dec 2012 | AIDS | Bamrasnaradura Infectious Diseases Institute | Completed | No outcome recorded |
| Phase 4 | NCT01258439 Comparator | Nov 2010 → Jul 2014 | HIV infectious disease, cardiovascular disorder | St Vincent's Hospital, Sydney | Completed | No outcome recorded |
| Phase 4 | NCT01225705 Comparator | Oct 2010 → Aug 2012 | HIV infectious disease, hepatitis C virus infection | University Hospital, Bonn | Withdrawn | No outcome recorded |
| Phase 4 | NCT01105611 Comparator | Aug 2010 → Dec 2012 | HIV infectious disease, hepatitis C virus infection | St. James's Hospital, Ireland | Unknown | No outcome recorded |
| Phase 4 | NCT01116817 Comparator | Aug 2010 → Jun 2011 | HIV infectious disease | Germans Trias i Pujol Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01118871 Comparator | May 2010 → May 2013 | HIV infectious disease | Imperial College London | Terminated | No outcome recorded |
| Phase 4 | NCT01102972 Comparator | Apr 2010 → Jun 2012 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 4 | NCT01513122 Comparator | Feb 2010 → Sep 2012 | HIV infectious disease | Kirby Institute | Completed | No outcome recorded |
| Phase 4 | NCT01166477 Background | Jan 2010 → Dec 2011 | HIV infectious disease | Sociedad Andaluza de Enfermedades Infecciosas | Completed | No outcome recorded |
| Phase 4 | NCT00994344 Background | Oct 2009 → Oct 2012 | HIV infectious disease | Germans Trias i Pujol Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00931463 Background | Sep 2009 → Sep 2012 | HIV infectious disease | Kirby Institute | Completed | No outcome recorded |
| Phase 4 | NCT01010399 Background | Sep 2009 → Nov 2010 | HIV infectious disease, hypertriglyceridemia | Felizarta, Franco, M.D. | Completed | No outcome recorded |
| Phase 4 | NCT00885482 Background | May 2009 → May 2010 | HIV infectious disease | Catholic University of the Sacred Heart | Completed | No outcome recorded |
| Phase 4 | NCT00782301 Comparator | Mar 2009 → Feb 2010 | HIV infectious disease, chronic hepatitis C virus infection, hepatitis B virus infection | ViiV Healthcare | Withdrawn | No outcome recorded |
| Phase 4 | NCT00762892 Comparator | Jan 2009 → Dec 2012 | HIV infectious disease | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT00677300 Background | Jan 2009 → Oct 2012 | HIV infectious disease | Dallas VA Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00757783 Background | Oct 2008 → Aug 2009 | HIV infectious disease | Tibotec, Inc | Completed | No outcome recorded |
| Phase 4 | NCT00772902 Background | Oct 2008 → Sep 2009 | — | Gilead Sciences | Completed | No outcome recorded |
| Phase 4 | NCT00765154 Comparator | Oct 2008 → Jul 2010 | HIV infectious disease | St Stephens Aids Trust | Terminated | No outcome recorded |
| Phase 4 | NCT00775606 Comparator | Oct 2008 → Dec 2010 | AIDS | Rush University Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT00759070 Comparator | Sep 2008 → Jul 2013 | HIV infectious disease | Juan A. Arnaiz | Unknown | No outcome recorded |
| Phase 4 | NCT00756730 Background | Sep 2008 → Jun 2011 | HIV infectious disease | Community Research Initiative of New England | Completed | No outcome recorded |
| Phase 4 | NCT00717067 Background | Jul → Nov 2008 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 4 | NCT01810887 Background | May → Jul 2008 | — | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 4 | NCT00611039 Comparator | Feb 2008 → Jul 2009 | HIV infectious disease | Germans Trias i Pujol Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00544128 Comparator | Oct 2007 → Feb 2012 | HIV infectious disease | International Medical Center of Japan | Completed | No outcome recorded |
| Phase 4 | NCT00531557 Background | Sep 2007 → Nov 2008 | HIV infectious disease | St Stephens Aids Trust | Completed | No outcome recorded |
| Phase 4 | NCT00552240 Comparator | Sep 2007 → Mar 2010 | HIV infectious disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT00540137 Comparator | Jul 2007 → Dec 2012 | HIV infectious disease | Imperial College London | Completed | No outcome recorded |
| Phase 4 | NCT00444379 Comparator | Apr 2007 → Feb 2012 | HIV infectious disease, Kaposi's sarcoma | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT00335322 Comparator | Feb 2007 → Mar 2011 | HIV infectious disease | Kirby Institute | Completed | No outcome recorded |
| Phase 4 | NCT00355719 Background | Jan 2007 → Feb 2008 | HIV infectious disease | Germans Trias i Pujol Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00384904 Comparator | Dec 2006 → Dec 2007 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 4 | NCT00438152 Comparator | Sep 2006 → Feb 2009 | HIV infectious disease | Royal Free Hampstead NHS Trust | Completed | No outcome recorded |
| Phase 4 | NCT01388543 Background | Sep 2006 → Jun 2008 | HIV infectious disease | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 4 | NCT00426296 Background | Aug 2006 → ? | HIV infectious disease, lipodystrophy | Clinical Alliance for Research & Education - Infectious Diseases, LLC. | Unknown | No outcome recorded |
| Phase 4 | NCT00389402 Background | Jul 2006 → Jul 2008 | HIV infectious disease | International Antiviral Therapy Evaluation Center | Completed | No outcome recorded |
| Phase 4 | NCT00810108 Background | Jun 2006 → May 2009 | AIDS-related disorder, HIV infectious disease | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | No outcome recorded |
| Phase 4 | NCT00281606 Comparator | Feb 2006 → Oct 2007 | HIV infectious disease | University of California, San Diego | Completed | No outcome recorded |
| Phase 4 | NCT00224445 Background | Sep 2005 → Jan 2007 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 4 | NCT00244712 Comparator | Jul 2005 → Apr 2008 | HIV infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00135356 Comparator | Jul 2005 → Jul 2007 | AIDS dysmorphic syndrome | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 4 | NCT00979706 Comparator | Mar 2005 → Nov 2014 | HIV infectious disease | Juan A. Arnaiz | Completed | No outcome recorded |
| Phase 4 | NCT00162643 Background | Dec 2004 → Dec 2007 | AIDS | National Institute of Medical Sciences and Nutrition Salvador Zubiran | Unknown | No outcome recorded |
| Phase 4 | NCT00084253 Comparator | Jun 2004 → Aug 2006 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 4 | NCT00242216 Comparator | May 2004 → Mar 2010 | HIV infectious disease | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT01445223 Comparator | Apr 2004 → Dec 2009 | HIV infectious disease | Göteborg University | Completed | No outcome recorded |
| Phase 4 | NCT00648999 Comparator | Nov 2003 → Dec 2006 | HIV infectious disease | AbbVie | Completed | No outcome recorded |
| Phase 4 | NCT00335686 Comparator | Oct 2003 → Mar 2006 | HIV infectious disease | Germans Trias i Pujol Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00234975 Comparator | Oct 2002 → Jan 2008 | HIV infectious disease | AbbVie | Completed | No outcome recorded |
| Phase not applicable19 trials | ||||||
| — | NCT06106126 Background | Feb 2023 → Feb 2024 | pneumonia | Fujian Akeylink Biotechnology Co., Ltd. | Unknown | No outcome recorded |
| — | NCT05044962 Comparator | Nov 2021 → Mar 2027 expected | HIV infectious disease | University of Alabama at Birmingham | Recruiting | No outcome recorded |
| — | NCT04380818 Background | Jun 2020 → Sep 2021 | viral pneumonia | Grupo de Investigación Clínica en Oncología Radioterapia | Unknown | No outcome recorded |
| — | NCT04394182 Background | Apr → Dec 2020 | cytokine release syndrome, viral pneumonia | Fundacion GenesisCare | Suspended | No outcome recorded |
| — | NCT04376814 Comparator | Mar → Apr 2020 | COVID-19 | Baqiyatallah Medical Sciences University | Completed | No outcome recorded |
| — | NCT04295551 Background | Mar → Jul 2020 | COVID-19 | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
| — | NCT04251871 Comparator | Jan 2020 → Jan 2021 | COVID-19 | Beijing 302 Hospital | Unknown | No outcome recorded |
| — | NCT02652793 Background | Nov 2015 → Nov 2018 | HIV infectious disease | Judit Pich | Completed | No outcome recorded |
| — | NCT01583439 Background | Sep 2012 → Feb 2013 | HIV infectious disease | Harvard School of Public Health (HSPH) | Terminated | No outcome recorded |
| — | NCT01614405 Comparator | Jun 2012 → Jul 2015 | primary biliary cholangitis | University of Alberta | Terminated | No outcome recorded |
| — | NCT00802074 Comparator | Dec 2008 → Mar 2009 | — | Garden State Infectious Disease Associates, PA | Completed | No outcome recorded |
| — | NCT00884793 Background | Sep 2008 → Dec 2009 | HIV infectious disease | University of California, San Francisco | Completed | No outcome recorded |
| — | NCT00614991 Comparator | Jan → Mar 2008 | — | Garden State Infectious Disease Associates, PA | Completed | No outcome recorded |
| — | NCT00428116 Comparator | Sep 2007 → Jul 2013 | HIV infectious disease | University of Washington | Terminated | No outcome recorded |
| — | NCT00413153 Comparator | May 2006 → Dec 2008 | HIV infectious disease | Massachusetts General Hospital | Completed | No outcome recorded |
| — | NCT00192608 Background | Nov 2004 → May 2006 | HIV infectious disease | Kirby Institute | Completed | No outcome recorded |
| — | NCT00051831 Background | Oct 2003 → Dec 2007 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| — | NCT00122590 Background | Jul 2002 → Mar 2005 | HIV infectious disease | French National Agency for Research on AIDS and Viral Hepatitis | Terminated | No outcome recorded |
| — | NCT00028314 Background | Mar 2002 → Mar 2005 | HIV wasting syndrome, lipodystrophy | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT00245739 Background | — | HIV infectious disease | Tibotec Pharmaceuticals, Ireland | Approved for marketing | No outcome recorded |
Press releases naming this drug 27 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-02-27 | AbbVie | AbbVie Statement on Coronavirus and lopinavir/ritonavir abbvie.com ↗ |
| 2017-02-27 | AbbVie | AbbVie Receives CHMP Positive Opinion for Eight-Week Treatment Option with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for Patients with Genotype 1b Chronic Hepatitis C abbvie.com ↗ |
| 2016-09-23 | AbbVie | AbbVie Presents Data on Eight-Week Treatment of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) in Patients with Genotype 1b Chronic Hepatitis C abbvie.com ↗ |
| 2016-07-25 | AbbVie | CHMP Grants Positive Opinion for Shorter Treatment Duration with AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) for Patients with Genotype 4 Chronic Hepatitis C with Compensated Cirrhosis (Child-Pugh A) abbvie.com ↗ |
| 2016-07-25 | AbbVie | AbbVie Receives U.S. FDA Approval of Once-Daily VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C abbvie.com ↗ |
| 2016-04-25 | AbbVie | AbbVie Receives U.S. FDA Approval of Supplemental New Drug Application for VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) without Ribavirin in Genotype 1b Chronic Hepatitis C Patients with Compensated Cirrhosis abbvie.com ↗ |
| 2016-04-15 | AbbVie | AbbVie Announces Real-World Data with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets) from Large German Hepatitis C-Registry abbvie.com ↗ |
| 2016-04-14 | AbbVie | AbbVie Announces High SVR Rates with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) Regardless of the Presence of Resistance-Associated Variants Prior to Treatment in Genotype 1 Chronic Hepatitis C Patients abbvie.com ↗ |
| 2016-03-30 | AbbVie | AbbVie to Present Data on VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets) and Investigational, Pan-Genotypic Regimen at The International Liver Congress™ 2016 abbvie.com ↗ |
| 2016-02-26 | AbbVie | AbbVie Receives CHMP Positive Opinion for VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) Without Ribavirin for the Treatment of Chronic Hepatitis C in Genotype 1b Patients with Compensated Cirrhosis (Child-Pugh A) in abbvie.com ↗ |
| 2016-01-07 | AbbVie | FDA Grants Priority Review to AbbVie for Supplemental New Drug Application for VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) without Ribavirin in Genotype 1b Chronic Hepatitis C Virus Patients with Compensated Cirrhosis abbvie.com ↗ |
| 2015-12-02 | AbbVie | AbbVie Announces FDA Acceptance of New Drug Application for a Once-Daily Formulation of VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) to Treat Genotype 1 Chronic Hepatitis C Virus Infection abbvie.com ↗ |
| 2015-11-14 | AbbVie | AbbVie Announces New Data on VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Patients with Chronic Hepatitis C Virus Infection With or Without Compensated Cirrhosis abbvie.com ↗ |
| 2015-10-01 | AbbVie | AbbVie Demonstrates Commitment to Hepatitis C Patients with New Data on VIEKIRA PAK™ (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) and Ongoing Clinical Development Program at The Liver Meeting® 2015 abbvie.com ↗ |
| 2015-09-28 | AbbVie | AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) Receives Approval in Japan for the Treatment of Genotype 1 Chronic Hepatitis C abbvie.com ↗ |
| 2015-09-11 | AbbVie | Ongoing Real World Study Reports High Sustained Viral Response Rates with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) in Genotype 1 Hepatitis C Patients abbvie.com ↗ |
| 2015-07-24 | AbbVie | TECHNIVIE™ (ombitasvir, paritaprevir, and ritonavir tablets) Receives FDA Approval as the First and Only All-Oral, Interferon-Free Treatment for Genotype 4 Chronic Hepatitis C in the U.S. abbvie.com ↗ |
| 2015-04-25 | AbbVie | AbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX® + EXVIERA® in Chronic Hepatitis C Patients with Renal Impairment at The International Liver Congress™ 2015 abbvie.com ↗ |
| 2015-02-23 | AbbVie | Results from AbbVie's Study of VIEKIRA PAK™ (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) Published Online in JAMA; Sub-analyses to be Presented at the Annual Confere abbvie.com ↗ |
| 2015-01-16 | AbbVie | European Commission Grants Marketing Authorizations for AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for the Treatment of Chronic Hepatitis C abbvie.com ↗ |
| 2014-12-19 | AbbVie | AbbVie Receives U.S. FDA Approval of VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C abbvie.com ↗ |
| 2014-11-21 | AbbVie | CHMP Grants Positive Opinions of AbbVie's VIEKIRAX™ (ombitasvir/paritaprevir/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe abbvie.com ↗ |
| 2014-07-22 | Pfizer | ViiV Healthcare presents phase III data comparing once-daily maraviroc in combination with darunavir/ritonavir with emtricitabine/tenofovir plus darunavir/ritonavir in treatment-naïve adults with HIV-1 pfizer.com ↗ |
| 2012-07-24 | Gilead Sciences | Gilead’s Boosting Agent Cobicistat for HIV Therapy as Effective as Ritonavir in Pivotal Phase 3 Study gilead.com ↗ |
| 2006-08-17 | Vertex Pharmaceuticals Incorporated | Head-to-Head Study Comparing LEXIVA(R) (fosamprenavir calcium) to Kaletra Presented at IAC 2006 and Published in The Lancet vrtx.com ↗ |
| 2006-05-16 | Vertex Pharmaceuticals Incorporated | GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results from Head-to-Head Clinical Study of HIV Protease Inhibitors Lexiva (Telzir) and Kaletra in Treatment-naive Patients with HIV vrtx.com ↗ |
| 2002-02-25 | Gilead Sciences | Viread Demonstrates Anti-HIV Potency Similar to the Protease Inhibitor Ritonavir in Short-Term Study of Treatment-Naive Patients gilead.com ↗ |
Evidence & citations 35 cited values
Every value below carries the sentence it was read from. 848 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ritonavir | “This international, phase 2, open-label, multicenter study (ClinicalTrials.gov Identifier: NCT01609933) was conducted to evaluate the safety and efficacy of an enhanced regimen...” PMID 30858739 ↗ Feb 2019814“Generic names: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine,...” NCT00624195 ↗ “It may include one or two nucleoside reverse transcriptase inhibitors, such as zidovudine, didanosine, lamuvidine, zalcitabine, stavudine), a non- nucleoside reverse...” NCT00032669 ↗ “The hypothesis for this study is whether a treatment regimen containing Atazanavir in combination with Ritonavir will work as well as other regimens containing a protease...” NCT00940771 ↗ “An Open Label, Randomised, Parallel Group Study of the Drug-drug Pharmacokinetic Interaction of Steady State Tipranavir (SEDDS SEC) 500 mg and Ritonavir (Soft Gelatin Capsules)...” NCT02251873 ↗ “BACKGROUND: In this phase 3 trial we evaluated the efficacy and safety of the interferon-free combination of ABT-450 with ritonavir (ABT-450/r), ombitasvir (also known as...” PMID 24720679 ↗ Apr 2014 “Participants stayed on their baseline emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)-containing regimen E/C/F/TDF; efavirenz (EFV)/FTC/TDF; ritonavir (RTV)-boosted...” NCT01815736 ↗ “This cohort will receive ModraDoc006/r 30 mg oral docetaxel in combination with 200 mg ritonavir in the morning and 20 mg oral docetaxel in combination with 100 mg ritonavir in...” NCT04028388 ↗ “Six hundred and eighty-eight antiretroviral-naive, HIV-1-infected patients were randomized in this double-blind, placebo-matched, multicenter, noninferiority study to receive a...” PMID 19542866 ↗ Jul 2009 “One 100 mg ritonavir capsule administered twice daily at 7:00 a.m. and 7:00 p.m. on Days 15 to 18 without regard to meals, then along with colchicine at 7:00 a.m. on Day 19...” NCT00983515 ↗ “ART that concurrently contains combinations of non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as efavirenz, and protease-inhibitors (PIs), such as...” NCT05044962 ↗ “The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside polymerase inhibitor), and ribavirin has...” PMID 24818763 ↗ May 2014 “This 48-week randomized study examined the safety and efficacy of a switch in CART to a once-daily regimen of saquinavir (SQV), ritonavir (RTV), and atazanavir (ATV) that did...” PMID 17479946 ↗ Apr 2007 “Individuals attending the emergency room because of potential sexual exposure to HIV were randomized to tenofovir disoproxil/emtricitabine (245/200 mg) plus either...” PMID 26994089 ↗ Mar 2016 “one tablet of Truvada a day at standard dose of Tenofovir 300mg and Emtricitabine 200mg and four tablets of Kaletra once a day for a total dose of lopinavir 800mg and ritonavir...” NCT01614405 ↗ “GIFT-I is a phase 3 trial evaluating the efficacy and safety of a 12-week regimen of coformulated ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) for treatment of Japanese...” PMID 26147154 ↗ Aug 2015 “The first-line combination provided to pregnant women will be standardized following consultation with the Ministry of Health, but will likely include ZDV, lamivudine (3TC) and...” NCT00753324 ↗ “The purpose of this study is to determine the effectiveness, safety, and tolerability (how well the body stands the drug) of an investigational protease inhibitor (PI) called...” NCT00071097 ↗ “Ritonavir: antiretroviral protease inhibitor, widely used in combination with other protease inhibitors in the therapy and prevention of HIV infection, which causes the...” NCT06676410 ↗ “The combination of ombitasvir (an NS5A inhibitor), paritaprevir (an NS3/4A inhibitor) coadministered with ritonavir (r), and dasabuvir (an NS5B nonnucleoside polymerase...” PMID 26596948 ↗ Nov 2015 “one recipient is treated with fixed-dose combination of ombitasvir (12.5 mg), paritaprevir (75 mg) and ritonavir (50 mg) + weight based ribavirin due to having persistent renal...” NCT03133065 ↗ “A Monocenter Randomized Double-blind Placebo-controlled Study to Investigate Neuropsychiatric Manifestations of HCV-infection During and After Treatment With...” NCT03003338 ↗ “We propose to treat 21 adult patients with chronic delta hepatitis using the combination of the farnesyltransferase inhibitor (FTI) lonafarnib (LNF) and the protease inhibitor...” NCT02511431 ↗ “Evaluation of the Pharmacokinetics and Tolerability of Increased Dosage of Lopinavir/Ritonavir(LPV/r) in Individuals Experiencing Viremia on Standard Dose LPV/r Using LPV/r...” NCT00414284 ↗ “Tenofovir / emtricitabine + lopinavir / ritonavir for all HIV-1+2-infected patients and all women who do not use effective contraception or who have a history of nevirapine use...” NCT00495651 ↗ “Boosted protease inhibitor (limited to darunavir \[DRV\] or atazanavir with low-dose ritonavir \[rtv\] or cobicistat \[COBI\], or lopinavir with rtv) as per current treatment regimen.” NCT02269917 ↗ “The preferentially recommended treatment of the study is atazanavir boosted with ritonavir, associated with a fixed combination of abacavir and lamivudine or emtricitabine + tenofovir” NCT00820118 ↗ “Any approved antiretroviral protease inhibitor such as atazanavir, darunavir, indinavir, ritonavir, and saquinavir ; consistent with the most recent prescribing information documents” NCT02556268 ↗ “(Fosamprenavir, atazanavir, lopinavir or darunavir) boosted with 100 mg of ritonavir, or atazanavir (400 mg / d) not boosted with ritonavir,if the 2 NRTIs are abacavir + Lamivudine” NCT02513147 ↗ “Relative Bioavailability of Tipranavir (TPV)/Ritonavir (RTV) at Steady State Administered as Oral Solutions vs. Capsules in the Fed and Fasted State in Healthy Volunteers” NCT02227017 ↗ “This is an open-label clinical trial treating 30 adult patients with chronic delta hepatitis with peginterferon lambda and lonafarnib boosted with ritonavir for 48 weeks.” NCT05953545 ↗ “Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients.” PMID 29909549 ↗ Feb 2019 “We enrolled women with HIV who were either ART-naive (control group; n=25), receiving efavirenz-based ART (n=25), or receiving atazanavir-ritonavir-based ART (n=24).” PMID 31498109 ↗ Sep 2019 “ModraDoc006 is a novel docetaxel tablet formulation that is co-administrated with the cytochrome P450 3A4 and P-glycoprotein inhibitor ritonavir (r): ModraDoc006/r.” PMID 33464545 ↗ Jan 2021 “OBJECTIVE: In POWER 1 and POWER 2, darunavir (TMC114) with low-dose ritonavir (darunavir/r) demonstrated greater efficacy versus control protease inhibitors (PIs).” PMID 17621237 ↗ Sep 2007 “The purpose of this study is to determine whether there is a drug interaction between GSK1349572 and the HIV protease inhibitors Tipranavir/Ritonavir (TPV/RTV).” NCT01068925 ↗ “Atazanavir (300 mg once daily) and lopinavir (400 mg twice daily), each with low-dose ritonavir, achieved similar IQs in HIV-infected, treatment-naive patients.” PMID 22121190 ↗ Nov 2011 “Likely consisting of an Nucleoside reverse-transcriptase inhibitor (NRTI) backbone i.e. Truvada plus a ritonavir-boosted protease inhibitor (PI) e.g. Darunavir” NCT02336074 ↗ “Participants were randomly assigned to receive usual care plus nirmatrelvir (300 mg)-ritonavir (100 mg) twice a day for 5 days or to receive usual care alone.” PMID 42019019 ↗ Apr 2026 “emtricitabine 200mg/TDF 300mg (1 pill per day) + efavirenz 600mg (1 pill per day) or lopinavir/ritonavir (3 pills twice a day) + enfuvirtide 90mg twice a day” NCT00454337 ↗ “Protease inhibitors (PIs) included amprenavir, atazanavir, darunavir, fosamprenavir, Kaletra (lopinavir/ritonavir, coformulated), ritonavir, and saquinavir.” NCT01252940 ↗ “Participants received 100 mg ritonavir at -12, 0, 12, and 24 h, with a single 150 mg dose of GST-HG171 co-administered at 0 h to maintain CYP3A inhibition.” PMID 42455066 ↗ Jul 2026 “To demonstrate that tipranavir (TPV) co-administered with ritonavir (RTV) does not affect the QT interval more than placebo co-administered with ritonavir” NCT02248883 ↗ “The purpose of this study is to learn about the bioequivalence of nirmatrelvir plus ritonavir after taking 2 different combination tablet forms by mouth.” NCT06397144 ↗ “atazanavir 300 mg and ritonavir 100 mg once daily or lopinavir 400 mg and ritonavir 100 mg twice daily plus two NRTIs; boosted protease inhibitor group” PMID 40883049 ↗ Sep 2025 “Kaletra® (lopinavir+ritonavir) is a combination of two protease inhibitors: lopinavir plus a low dose of ritonavir, enhancing the action of the former.” NCT00865475 ↗ “Patients will receive oral docetaxel (as ModraDoc006 10 mg tablets) and ritonavir (100 mg tablet) once- or bi-daily, once a week in a fasted condition.” NCT03150368 ↗ “Lersivirine 750 mg tablets PO taken once daily + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules PO taken twice daily + 1 optimized NRTI” NCT01254656 ↗ “VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets) + RBV (ribavirin tablets) for 12 weeks” NCT02461745 ↗ “atazanavir 300 mg + raltegravir 400 mg twice daily for 4 weeks then atazanavir 300 mg + ritonavir 100 mg + raltegravir 800 mg once daily for 4 weeks” NCT00874523 ↗ “Nirmatrelvir/r is a combination of two molecules: nirmatrelvir which is a protease inhibitor (against 3CL) and ritonavir which has a booster role.” NCT07406217 ↗ “either continue on their current regimen or one of two study arms (atazanavir 300mg plus ritonavir 100mg daily plus raltegravir 400mg twice daily” NCT00931801 ↗ “once daily integrase inhibitor administered with darunavir/ritonavir (DRV/r) in HIV-1 infected, virologically suppressed paediatric participants” NCT02383108 ↗ “Plasma concentrations of saquinavir, lopinavir and ritonavir were determined using a validated high performance liquid chromatography technique.” PMID 16220084 ↗ Oct 2005 “Every participant recieves 2 tablets of TMC114, 300 mg, combined with one tablet of rtv (ritonavir), 100mg, orally twice daily, every 12 hours” NCT02187107 ↗ “Population PK models were developed for lopinavir (LPV) and ritonavir (RTV) to evaluate the impact of RTV on the oral clearance (CL/F) of LPV.” PMID 38247190 ↗ Jan 2024 “PIs used as study drugs will include atazanavir (+/- ritonavir), fosamprenavir (+/-ritonavir), lopinavir/ritonavir, and darunavir/ritonavir.” NCT00884793 ↗ “The preferred study-supplied HAART regimen was lopinavir/ritonavir (LPV/RTV) plus fixed dose combination tenofovir/emtricitabine (TDF/FTC).” NCT00955968 ↗ “Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets in fed or fasting condition” NCT05084456 ↗ “Single oral dose of 300 mg \[14C\]PF-07321332 containing approximately 100 µCi \[14C\]PF-07321332 coadministered with 100 mg ritonavir.” NCT05178654 ↗ “darunavir and ritonavir concentrations in plasma will be determined by high performance liquid chromatography using a validated method.” NCT01346982 ↗ “switch the protease inhibitor for oral atazanavir 200 mg and ritonavir 100 mg or for atazanavir 300 mg and ritonavir 100 mg once daily” PMID 27470026 ↗ May 2016 “Patients on second line antiretroviral therapy take 2 NRTIs and either protease inhibitor lopinavir/ritonavir or atazanavir/ritonavir.” NCT02155101 ↗ “ritonavir (RTV) effectively boosts most protease inhibitors but is associated with significant dose-dependent adverse events (AEs).” PMID 21126954 ↗ Sep 2010 “Treatment with twice daily once weekly (BIDW) ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets” NCT03890744 ↗ “12 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir (25/150/100 mg dose) once daily and Dasabuvir 250 mg twice daily.” NCT02646111 ↗ “Each tablet of Kaletra contains 200 mg of Lopinavir and 50mg of ritonavir. The patients will take two tablets of Kaletra bid.” NCT01031849 ↗ “Darunavir is a human immunodeficiency virus type 1 (HIV-1) protease inhibitor boosted with ritonavir (DRV/r) or cobicistat.” PMID 33367975 ↗ Dec 2020 “Ombitasvir, paritaprevir with ritonavir (OBV/PTV/r) ± ribavirin (RBV) are approved to treat HCV genotype 4 (GT4) infection.” NCT04378608 ↗ “Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients” NCT04391985 ↗ “Aluvia(Lopinavir / Ritonavir tablets): 400 mg/100 mg (2 tablets) each time, 2 time a day, orally, for 5 consecutive days.” NCT07002242 ↗ “Each capsule contains Lopinavir (40mg), Ritonavir (10mg), Abacavir (30mg) and Lamivudine (15mg) in granules formulation.” NCT03836833 ↗ “As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.” NCT00772902 ↗ “Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.” PMID 19487905 ↗ Aug 2009 “A Phase IV Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir for Chronic Hepatitis C Genotype 1 Virus Infection” NCT02498015 ↗ “Patients will take oral doses of 600 mg of TMC114 twice daily in combination with 100 mg of ritonavir twice daily” NCT00245739 ↗ “The study treatment during the pregnancy is: darunavir 600 mg + ritonavir 100 mg 2 times 24 (DRV/r) monotherapy” NCT02738502 ↗ “Oral docetaxel requires co-administration ritonavir (r), which might further impact the pharmacokinetics (PK).” PMID 33744986 ↗ Mar 2021 “Paritaprevir/ritonavir/ombitasvir (PTV/r/OBV, 75mg/50mg/12.5mg per tablet, Viekirax): 2 tablets per os per day” NCT02874066 ↗ “We investigated whether dose escalation of atazanavir/ritonavir could safely overcome the DDI with rifampicin.” PMID 37982585 ↗ May 2024 “Darunavir/ritonavir 400/100mg (DRV/r) once daily plus nucleoside/nucleotide reverse transcriptase inhibitors.” NCT02671383 ↗ “Branded ATV 200 mg/capsule was taken with generic ritonavir 100 mg/tablet once daily plus TDF and lamivudine.” PMID 24983717 ↗ Dec 2014 “In the first phase (phase A), ritonavir-boosted lopinavir (Kaletra®) will be compared with continued HAART.” NCT00531986 ↗ “TMC114 300mg are orange tablets where 2 tablets are taken by mouth twice a day with 1 tablet of Ritonavir.” NCT00110877 ↗ “Lexiva (fosamprenavir 1400 mg) + Norvir (ritonavir 100 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)” NCT00727597 ↗ “The aim of this study was to determine the impact of sex on the pharmacokinetics of lopinavir/ritonavir.” PMID 17615254 ↗ Jul 2007 “one (100mg ritonavir tablet and two 150mg nirmatrelvir tablets) taken orally in the morning and evening” NCT07597902 ↗ “maraviroc (Selzentry, Celsentri) 150mg QD + atazanavir (Reyataz) /ritonavir (Norvir) (300/100mg) QD” NCT00827112 ↗ “atazanavir (ATV) plus ritonavir (RTV) or lopinavir (LPV)/RTV are the preferred boosted PI options.” NCT02227238 ↗ “oral lopinavir 400 mg and oral ritonavir 100 mg twice daily plus oral lamivudine 300 mg once daily” PMID 26062880 ↗ Jun 2015 “TLC-ART 101 contains lopinavir, ritonavir, and tenofovir in a combination nanoparticle suspension” NCT05850728 ↗ “One time bi-daily dosing (30/20 mg) of ModraDoc006 in combination with ritonavir 100 mg tablets” NCT05242926 ↗ “During all treatment periods 100 mg ritonavir (rtv) will be dosed once daily on Day 1 to Day 5.” NCT01052883 ↗ “ASC09F (300 mg ASC09 and 100 mg Ritonavir) one tablet at a time, once per day, up to 7 days.” NCT04547894 ↗ “Prezista® (darunavir)/ Norvir® (ritonavir) (switch for a drug with a higher genetic barrier)” NCT02247687 ↗ “once-daily darunavir 800 mg [two 400 mg tablets] boosted with ritonavir 100 mg [one tablet]” PMID 28566227 ↗ May 2017 “either an FDC of danoprevir and ritonavir or danoprevir and ritonavir as separate tablets” NCT01592318 ↗ “It is a combination of two anti-HIV medicines called darunavir (DRV) and ritonavir (RTV).” NCT06139796 ↗ “two 75 mg ABT-450/50 mg ritonavir/12.5 mg ABT-267 tablets taken orally every morning (QD)” NCT02167945 ↗ “Kaletra® is 2 protease inhibitors (lopinavir and ritonavir) combined in one dosage form.” NCT00508222 ↗ “Either Once Daily Atazanavir/Ritonavir (ATV/r) or Once Daily Darunavir/Ritonavir (DRV/r)” NCT00756730 ↗ “ritonavir (RTV)-boosted or cobicistat (COBI)-boosted atazanavir (ATV) or darunavir (DRV)” NCT02603107 ↗ “1 fully-active ritonavir-boosted protease inhibitor (PI/r) plus 1 or 2 additional agents” NCT00708162 ↗ “Patients are treated with ritonavir 100mg boosted atazanavir 300mg along with Epzicom.” NCT00280969 ↗ “ABT-450/r/ABT-267 (paritaprevir/ritonavir/ombitasvir; 2 direct acting antiviral agent” NCT02247401 ↗ “Atazanavir is a first-line HIV protease inhibitor commonly co-dosed with ritonavir.” PMID 22394315 ↗ Apr 2012 “Lopinavir/Ritonavir 200/50 mg 2 cpr BID monotherapy - 26 weeks (A) or 24 weeks (B)” NCT00437476 ↗ “ABT-450 co-formulated with ritonavir and ABT-267 (ABT-450/r/ABT-267) and ABT-333” NCT02219490 ↗ “Paxlovid® (300mg nirmatrelvir + ritonavir 100mg) twice a day (BD) for 5 days.” NCT04746183 ↗ “switching to lopinavir-ritonavir plus nevirapine (nevirapine group; n = 34)” PMID 19663689 ↗ Sep 2009 “Ritonavir (RTV; /r) 100 mg capsule administered orally once daily with food” NCT00445146 ↗ “Ritonavir (RTV) 100 mg soft gelatin capsule administered orally once daily” NCT00892437 ↗ “atazanavir 300mg + ritonavir 100mg + tenofovir 300mg/emtricitabine 200mg” NCT01102972 ↗ “Atanazir 300 mg once dailly boosted with 100 mg of ritonavir once dailly” NCT02652793 ↗ “Day 1\~5: 300 mg of Nirmatrelvir and 100 mg of ritonavir, Q12H X 5 days” NCT05341609 ↗ “All subjects will receive Ombitasvir+Paritaprevir+Ritonavir (Viekirax).” NCT03050905 ↗ “Lopinavir/ritonavir 400/100mg bid or Lopinavir/ritonavir 600/150mg bid” NCT01138202 ↗ “500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID” NCT00144105 ↗ “tipranavir/ritonavir (TPV 500 mg/RTV 100 mg and TPV 750 mg/RTV 200 mg)” NCT02253823 ↗ “An arm to change the regimen to: raltegravir and darunavir/ritonavir” NCT01294761 ↗ “A combination of 5-day remdesivir and 10-day Nirmatrelvir/Ritonavir” NCT06610643 ↗ “Paxlovid (Nirmatrelvir+ Ritonavir , boosted 3CL-protease inhibitor)” NCT07157007 ↗ “SSD8432 300mg in combination with ritonavir 100mg, day1--day5,BID” NCT05373446 ↗ “once daily Kaletra dosed at 800mg lopinavir with 200mg ritonavir” NCT00679926 ↗ “ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet” NCT01854697 ↗ “ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet” NCT01854528 ↗ “ABT-450 coformulated with ritonavir and ABT-267; ABT-333 tablet” NCT01704755 ↗ “ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet” NCT01767116 ↗ “ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet” NCT01995071 ↗ “ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet” NCT01833533 ↗ “Paxlovid contains two medicines: nirmatrelvir and ritonavir.” NCT05386433 ↗ “Ritonavir (RTV) 100 mg tablet administered orally once daily” NCT01108510 ↗ “Paxlovid (nirmatrelvir 300mg, ritonavir 100mg) bid x 25 days” NCT05595369 ↗ “monotherapy with ritonavir-boosted lopinavir or darunavir” NCT01480713 ↗ “the protease inhibitor ABT-450 with ritonavir (ABT-450/r)” PMID 24720703 ↗ Apr 2014 “rilpivirine 25mg plus darunavir 800mg/ritonavir 100mg QD” NCT01792570 ↗ “Tablet; ABT-450 coformulated with ritonavir and ABT-267” NCT01911845 ↗ “atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®)” NCT02616783 ↗ “Aluvia (lopinavir/ritonavir 400mg/100mg), twice daily” NCT00988039 ↗ “Darunavir/ritonavir (400/100mg) q 12 hours for 5 days” NCT04435587 ↗ “atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®)” NCT02605954 ↗ “a low-dose ritonavir (rtv)-boosted protease inhibitor” NCT00665847 ↗ “protease inhibitor (PI) boosted with ritonavir (RTV)” NCT01475838 ↗ “Saquinavir 1000mg + Ritonavir 100mg Bd for 24 weeks” NCT00438152 ↗ “Maraviroc 300 mg Darunavir 800 mg Ritonavir 100 mg” NCT01367210 ↗ “Lopinavir/Ritonavir (LPV/r) + Raltegravir (RAL)” NCT00752856 ↗ “dose of 750 mg SIM0417 with 100 mg ritonavir.” NCT05506176 ↗ “pharmacologic booster cobicistat or ritonavir” NCT03631732 ↗ “Kaletra: lopinavir/ritonavir: 2c/12h 7 days” NCT04374539 ↗ “lopinavir/ritonavir cps 200/50 mg, 2x2/day” NCT04475120 ↗ “ritonavir-boosted lopinavir (400/100 mg)” PMID 26994091 ↗ Mar 2016 “taken with Ritonavir 100 mg twice a day” NCT01641367 ↗ “dual-PI regimen (saquinavir/ritonavir)” NCT00001087 ↗ “Atazanavir + Fosamprenavir + ritonavir” NCT00122603 ↗ “tipranavir (TPV) and ritonavir (RTV)” NCT02251132 ↗ “ritonavir-boosted atazanavir (ATV/r)” NCT02121795 ↗ “Tablet; ABT-450; Capsule; ritonavir” NCT01685203 ↗ “Nirmatrevlir / Ritonavir (Paxlovid)” NCT05271929 ↗ “Oral darunavir+ritonavir 600/100mg” NCT03589040 ↗ “atazanavir (ATV) + ritonavir (RTV)” NCT02469246 ↗ “ritonavir (RTV)-boosted atazanavir” NCT02246998 ↗ “saquinavir (SQV), ritonavir (RTV)” NCT00039741 ↗ “SSD8432 750mg and Ritonavir 100mg” NCT05373433 ↗ “Darunavir 800mg+Ritonavir 100mg” NCT06799650 ↗ “Lopinavir / Ritonavir （LPV/r)）” NCT02231281 ↗ “5. Ritonavir 100 mg once a day” NCT02588820 ↗ “ABT-450, ABT-267 and ritonavir” NCT02052362 ↗ “ritonavir 100 mg. p.o. b.i.d.” NCT00782301 ↗ “HS-10517 Dose 1+Ritonavir” NCT05779579 ↗ “Ritonavir oral solution” NCT00076999 ↗ “ritonavir 100 mg daily” NCT01367236 ↗ “Drug: Ritonavir” NCT00855335 ↗ “ritonavir 100mg” NCT02473328 ↗ “Ritonavir (RTV)” NCT02064842 ↗ “Ritonavir” NCT00985543 ↗ “ritonavir” NCT01637259 ↗ “ritonavir” NCT00122590 ↗ |
| Known as | A-84538 | ChEMBL registry synonym — accepted as the source's own label CHEMBL163 ↗ |
| Known as | ABBOTT-84538 | ChEMBL registry synonym — accepted as the source's own label CHEMBL163 ↗ |
| Known as | ABT-538 | “A Pilot Study to Evaluate the Immunologic Consequences of a Highly Active Antiretroviral Therapy Regimen (HAART) Consisting of Ritonavir (ABT-538), Zidovudine (AZT), and...” NCT00001075 ↗1“A Study of Ritonavir (ABT-538) When Used With Nelfinavir in HIV-Infected Patients” NCT00002201 ↗ |
| Known as | Empetus | ChEMBL registry synonym — accepted as the source's own label CHEMBL163 ↗ |
| Known as | Gammora | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06799650 ↗ |
| Known as | Kaletra | “It may include one or two nucleoside reverse transcriptase inhibitors, such as zidovudine, didanosine, lamuvidine, zalcitabine, stavudine), a non- nucleoside reverse...” NCT00032669 ↗16“The purpose of this study is to see if using a combination of other drug classes, like the ones that Kaletra® and Intelence™ belong to, can still help reduce the amount of HIV...” NCT01045369 ↗ “Second line regimen - ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir (Kaletra))” NCT00428116 ↗ “* ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir (kaletra))” NCT00427297 ↗ “Arm 1: Kaletra two tabs twice a day + Truvada one pill once a day.” NCT01234116 ↗ “Patients assigned to this arm will receive Trizivir and kaletra.” NCT00979706 ↗ “Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]” NCT04354428 ↗ |
| Known as | Lopinavir-ritonavir | “Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19.” PMID 36260627 ↗ Oct 202210“Kaletra (lopinavir/ritonavir) may be of benefit to patients with poor immune responses to HAART despite viral suppression.” NCT00145795 ↗ “Second line regimen - ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir (Kaletra))” NCT00428116 ↗ “ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir)” NCT00427297 ↗ “KALETRA (Lopinavir-ritonavir)” NCT00723775 ↗ “Kaletra (lopinavir/ritonavir)” NCT00102778 ↗ “Lopinavir-ritonavir” NCT01231685 ↗ “Lopinavir-ritonavir” NCT04354428 ↗ |
| Known as | LPV-RTV | “Lopinavir-ritonavir (LPV-RTV)” NCT01061151 ↗ |
| Known as | LPV/r | “Second line regimen - ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir (Kaletra))” NCT00428116 ↗2“ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir)” NCT00427297 ↗ “lopinavir-ritonavir (LPV/r)” NCT04354428 ↗ |
| Known as | Norvir | “This study is designed to evaluate the potential for an effect of Ritonavir (Norvir®) or omeprazole (Prilosec®) on the pharmacokinetics of samatasvir and to assess the safety...” NCT01813552 ↗17“Fosamprenavir (FPV, TELZIR) is currently licensed in Europe for twice daily (BID) dosing in combination with ritonavir (RTV, Norvir) as a boosting agent” NCT00450580 ↗ “The Pharmacokinetics of SAquinavir (Invirase New Tablet Formulation) 1,000mg + Ritonavir (Norvir) 100mg q12h in HIV-infected Pregnant Women (SARA)” NCT00145561 ↗ “Lexiva (fosamprenavir 1400 mg) + Norvir (ritonavir 100 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)” NCT00727597 ↗ “Norvir (ritonavir), a PI that has the ability to boost or increase the blood levels of other PIs” NCT00148785 ↗ “Lexiva (fosamprenavir calcium) 1400 mg per day, Norvir (ritonavir) 100 mg per day” NCT01010399 ↗ “Lamivudine (Epivir, GSK), Atazanavir (Reyataz, BMS), Ritonavir (Norvir, Abbott)” NCT01599364 ↗ “atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®)” NCT02605954 ↗ “atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®)” NCT02616783 ↗ “Ritonavir (Norvir): capsules 100 mg (1 capsule/24h)” NCT00355719 ↗ “ritonavir tablet (Norvir®): 100 mg QD.” NCT01033760 ↗ “Drug: Ritonavir (Norvir)” NCT00885482 ↗ “Norvir (Ritonavir)” NCT00002447 ↗ “ritonavir (Norvir)” NCT00877591 ↗ “ritonavir (Norvir)” NCT00426296 ↗ |
| Known as | norvir (ritonavir) | “norvir (ritonavir)” NCT02265237 ↗1“Norvir (ritonavir)” NCT01902186 ↗ |
| Known as | NRV | “Ritonavir (NRV)” NCT00158405 ↗ |
| Known as | NSC-693184 | ChEMBL registry synonym — accepted as the source's own label CHEMBL163 ↗ |
| Known as | RIT | “the combination of the HIV protease inhibitors (HIV-PIs) saquinavir and ritonavir (SQV+RIT) in patients with idiopathic pulmonary arterial hypertension (IPAH)” PMID 26401255 ↗ Sep 2015 |
| Known as | Ritomune | ChEMBL registry synonym — accepted as the source's own label CHEMBL163 ↗ |
| Known as | ritonavir = Norvir trade name | “ritonavir = Norvir trade name” NCT01047995 ↗ |
| Known as | ritonavir also known as norvir | “ritonavir also known as norvir” NCT02219477 ↗3“Ritonavir also known as norvir” NCT02216422 ↗ “ritonavir also known as Norvir” NCT01672983 ↗ “ritonavir also known as Norvir” NCT02023099 ↗ |
| Known as | Ritonavir component of kaletra | ChEMBL registry synonym — accepted as the source's own label CHEMBL163 ↗ |
| Known as | Ritonavir component of paxlovid | ChEMBL registry synonym — accepted as the source's own label CHEMBL163 ↗ |
| Known as | Ritonavir component of technivie | ChEMBL registry synonym — accepted as the source's own label CHEMBL163 ↗ |
| Known as | Ritonavir component of viekirax | ChEMBL registry synonym — accepted as the source's own label CHEMBL163 ↗ |
| Known as | Ritonavir component of xiannuoxin | ChEMBL registry synonym — accepted as the source's own label CHEMBL163 ↗ |
| Known as | Ritonavir mylan | ChEMBL registry synonym — accepted as the source's own label CHEMBL163 ↗ |
| Known as | Ritonavir related compounds mixture | ChEMBL registry synonym — accepted as the source's own label CHEMBL163 ↗ |
| Known as | Ritonavirum | ChEMBL registry synonym — accepted as the source's own label CHEMBL163 ↗ |
| Known as | ritonovir | “ritonovir” NCT00766818 ↗ |
| Known as | Ritovir | ChEMBL registry synonym — accepted as the source's own label CHEMBL163 ↗ |
| Known as | RTV | “DESIGN: ICE-001 is a phase IV, randomized, two-arm unblinded study, comparing the effect on immune reconstitution of open-label ritonavir (RTV)-enhanced lopinavir (LPV) to...” NCT00775606 ↗106“This is a Phase I, partially randomized, open-label, single-center, two-way, two-period cross-over study to investigate the pharmacokinetic interaction between etravirine (ETR)...” NCT01876966 ↗ “This study is a single-center, double-blind, randomized, placebo-controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study that will evaluate the safety,...” NCT02321384 ↗ “The purpose of this study is to see if it is safe to give saquinavir-SGC (SQV) combined with low-dose ritonavir (RTV) plus zidovudine (ZDV) and lamivudine (3TC) to HIV-positive...” NCT00000920 ↗ “In Pediatric AIDS Clinical Trials Group 377, antiretroviral therapy-experienced children were randomized to 4 treatment arms that included different combinations of stavudine,...” PMID 11372025 ↗ May 2001 “The efficacy and tolerance of switching from zidovudine (ZDV) and lamivudine (3TC) in clinically stable HIV-infected children with incomplete viral suppression to stavudine...” PMID 11840078 ↗ Feb 2002 “This 48-week randomized study examined the safety and efficacy of a switch in CART to a once-daily regimen of saquinavir (SQV), ritonavir (RTV), and atazanavir (ATV) that did...” PMID 17479946 ↗ Apr 2007 “Adult AIDS Clinical Trials Group 5043 examined pharmacokinetic (PK) interactions between amprenavir (APV) and efavirenz (EFV) both by themselves and when nelfinavir (NFV),...” PMID 16048950 ↗ Aug 2005 “Each regimen consists of 4 drugs that include a combination of nucleoside reverse transcriptase inhibitors (stavudine, lamivudine, zidovudine, didanosine, zalcitabine) plus...” NCT00000902 ↗ “This study will evaluate the predictive value of pharmacokinetic-adjusted phenotypic susceptibility (C12h/IC50) on ARV response to ritonavir (RTV)-boosted regimens in patients...” NCT00027339 ↗ “The purpose of this study is to determine whether two drugs, atazanavir (ATV) and ritonavir (RTV), will control HIV infection when taken together without any other anti-HIV...” NCT00084019 ↗ “The purpose of this study is to see if it is safe and effective to give ritonavir (RTV) plus lamivudine (3TC) plus zidovudine (ZDV) to HIV-infected pregnant women during...” NCT00000888 ↗ “saquinavir/ritonavir 1500/100 mg or 1500/50 mg Twenty HIV-infected volunteers on stable doses of SQV/RTV 1500/100 mg OD for at least 3 months with an NRTI backbone and...” NCT00622206 ↗ “The aim of this clinical trial is to compare the efficacy and safety of ritonavir (RTV)-boosted atazanavir with nevirapine, each on a background of emtricitabine and tenofovir...” NCT00552240 ↗ “The purpose of this study is to see whether taking indinavir (IDV) plus ritonavir (RTV) plus stavudine (d4T) plus lamivudine (3TC) 2 times each day is safe and can lower the...” NCT00002241 ↗ “Boosted protease inhibitor (limited to darunavir \[DRV\] or atazanavir with low-dose ritonavir \[rtv\] or cobicistat \[COBI\], or lopinavir with rtv) as per current treatment regimen.” NCT02269917 ↗ “Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV” NCT01138605 ↗ “The 7 drugs that will be given in this study are stavudine (d4T), didanosine (ddI), lamivudine (3TC), nelfinavir (NFV), ritonavir (RTV), saquinavir (SQV), and nevirapine (NVP).” NCT00001108 ↗ “In this study, the protease inhibitors indinavir (IDV) and ritonavir (RTV) will be studied in patients who have high levels of virus while taking other protease inhibitors.” NCT00001133 ↗ “Zidovudine (ZDV), lamivudine (3TC), stavudine (d4T), didanosine (ddI), delavirdine (DLV), ritonavir (RTV), and saquinavir soft gel capsules (SQV sgc) are provided on-study.” NCT00000891 ↗ “Relative Bioavailability of Tipranavir (TPV)/Ritonavir (RTV) at Steady State Administered as Oral Solutions vs. Capsules in the Fed and Fasted State in Healthy Volunteers” NCT02227017 ↗ “Nucleoside and ritonavir (RTV) toxicities have led to increased interest in nucleoside reverse transcriptase inhibitors (NRTIs) and RTV-sparing antiretroviral regimens.” PMID 22592092 ↗ May 2012 “PURPOSE: To compare the long-term clinical efficacy and toxicity of initial strategies of nelfinavir (NFV) or ritonavir (RTV) in patients with CD4+ cells below 200/mm3.” PMID 15002082 ↗ Jan 2004 “In this study we sought to evaluate narlaprevir (NVR) pharmacokinetics (PK) after a single dose with or without ritonavir (RTV) in cirrhotic versus healthy subjects.” PMID 27645244 ↗ Nov 2016 “The purpose of this study is to determine whether there is a drug interaction between GSK1349572 and the HIV protease inhibitors Tipranavir/Ritonavir (TPV/RTV).” NCT01068925 ↗ “Ritonavir (rtv) 100 mg taken by mouth following a meal each morning for 2 weeks during the Pre-Treatment Period and for 48 weeks during the Treatment Period.” NCT00896051 ↗ “To demonstrate that tipranavir (TPV) co-administered with ritonavir (RTV) does not affect the QT interval more than placebo co-administered with ritonavir” NCT02248883 ↗ “Tipranavir (TPV) plus ritonavir (RTV) is indicated for use as part of an antiretroviral treatment regimen for resistant HIV-1 infection in adult patients.” NCT00344123 ↗ “Fosamprenavir (FPV, TELZIR) is currently licensed in Europe for twice daily (BID) dosing in combination with ritonavir (RTV, Norvir) as a boosting agent” NCT00450580 ↗ “Population PK models were developed for lopinavir (LPV) and ritonavir (RTV) to evaluate the impact of RTV on the oral clearance (CL/F) of LPV.” PMID 38247190 ↗ Jan 2024 “The two combinations are abacavir/lamivudine/zidovudine (ABC/3TC/ZDV) and zidovudine/lamivudine (ZDV/3TC) plus lopinavir/ritonavir (LPV/RTV).” NCT00086359 ↗ “Effects of Tipranavir (TPV) and Ritonavir (RTV) on the Pharmacokinetic Characteristics of Tenofovir Disoproxil Fumarate in Healthy Volunteers” NCT02251145 ↗ “The preferred study-supplied HAART regimen was lopinavir/ritonavir (LPV/RTV) plus fixed dose combination tenofovir/emtricitabine (TDF/FTC).” NCT00955968 ↗ “Once Daily (QD) Dosing of Lonafarnib (LNF) Co-administered With Ritonavir (RTV) for Treatment of Chronic Hepatitis D Virus Infection” NCT05229991 ↗ “ritonavir (RTV) effectively boosts most protease inhibitors but is associated with significant dose-dependent adverse events (AEs).” PMID 21126954 ↗ Sep 2010 “optimal dose combination(s) of tipranavir (TPV) and ritonavir (RTV) for antiretroviral treatment naïve HIV-1 infected patients” NCT00530920 ↗ “nelfinavir (NFV) 30 mg/kg twice daily (bid), ritonavir (RTV) 400 mg/m bid and buffered didanosine (ddI) 240 mg/m daily (arm A)” PMID 16220085 ↗ Oct 2005 “concurrent tipranavir (TPV) and ritonavir (RTV) administration on the single dose pharmacokinetics of didanosine (ddI)” NCT02251873 ↗ “Ritonavir (RTV) is a protease inhibitor (PI) commonly used to increase drug levels of other PIs in HIV drug treatment.” NCT00028366 ↗ “Assessment of the interaction of tipranavir/ritonavir (TPV/RTV) and valaciclovir (VAL), a prodrug of aciclovir (ACV)” NCT02226978 ↗ “Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs)” NCT00135356 ↗ “We aimed to evaluate the pharmacokinetics of DRV, ritonavir (RTV), and DTG in the presence and absence of RIF.” PMID 35583344 ↗ May 2022 “GW433908/ritonavir (RTV) to viral response to nelfinavir (NFV) when used with abacavir (ABC)/lamivudine (3TC)” NCT00009061 ↗ “The other anti-HIV drugs used are abacavir (ABC), amprenavir (APV), ritonavir (RTV), and efavirenz (EFV).” NCT00002239 ↗ “Arm A: Saquinavir (SQV) plus ritonavir (RTV) plus delavirdine (DLV) plus adefovir dipivoxil placebo.” NCT00000892 ↗ “During all treatment periods 100 mg ritonavir (rtv) will be dosed once daily on Day 1 to Day 5.” NCT01052883 ↗ “ritonavir (rtv): type = exact number, unit = mg, number = 100, form = tablet, route = oral use” NCT01448707 ↗ “Study to characterize the effects of two dose combinations of Tipranavir (TPV)/Ritonavir (RTV)” NCT02245438 ↗ “indinavir (IDV) and ritonavir (RTV) in combination with stavudine (d4T) and lamivudine (3TC)” NCT00002451 ↗ “It is a combination of two anti-HIV medicines called darunavir (DRV) and ritonavir (RTV).” NCT06139796 ↗ “ritonavir (RTV)-boosted or cobicistat (COBI)-boosted atazanavir (ATV) or darunavir (DRV)” NCT02603107 ↗ “Ritonavir (RTV) plus soft gelatin capsule saquinavir (SQV-SGC) plus efavirenz (EFV).” NCT00000914 ↗ “Both ritonavir (RTV) and indinavir (IDV) are approved by the FDA to treat HIV” NCT00012519 ↗ “tipranavir (TPV) capsule + ritonavir (RTV) capsule + cocktail + digoxin oral” NCT02243553 ↗ “Ritonavir (RTV; /r) 100 mg capsule administered orally once daily with food” NCT00445146 ↗ “Ritonavir (RTV) 100 mg soft gelatin capsule administered orally once daily” NCT00892437 ↗ “fos-amprenavir (fAPV) boosted with either of two doses of ritonavir (RTV)” NCT00335270 ↗ “ritonavir (RTV) 100 mg capsules or 80 mg/mL oral solution once daily (QD)” NCT00040664 ↗ “tipranavir/ritonavir (TPV 500 mg/RTV 100 mg and TPV 750 mg/RTV 200 mg)” NCT02253823 ↗ “500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID” NCT00144105 ↗ “TMC114 boosted with low dose ritonavir (RTV) versus Kaletra (LPV)/RTV” NCT00110877 ↗ “Tenofovir (TDF) + emtricitabine (FTC) + lopinavir/ritonavir (LPV/RTV)” NCT00759070 ↗ “standard dual PI combination of saquinavir (SQV) and ritonavir (RTV)” NCT02239835 ↗ “steady-state Tipranavir (TPV) / Ritonavir (RTV) (500mg/200mg bid)” NCT02251171 ↗ “Ritonavir (RTV; /r) 100 mg tablet administered orally once daily” NCT01106586 ↗ “received atazanavir (ATV), 150 mg, and ritonavir (RTV), 80 mg” NCT01099579 ↗ “three dose combinations of tipranavir (TPV) / ritonavir (RTV)” NCT02251223 ↗ “Ritonavir (RTV) 100 mg tablet administered orally once daily” NCT01565889 ↗ “steady-state darunavir/ritonavir (DRV/rtv) 600/100 mg b.i.d.” NCT00775125 ↗ “one capsule of ritonavir (RTV), another protease inhibitor” NCT00389402 ↗ “with or without a low-dose boost of the PI ritonavir (RTV)” NCT00006604 ↗ “Regimen 1 consists of IDV, ritonavir (RTV), ddI, and HU.” NCT00000919 ↗ “a low-dose ritonavir (rtv)-boosted protease inhibitor” NCT00665847 ↗ “atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®)” NCT02605954 ↗ “atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®)” NCT02616783 ↗ “protease inhibitor (PI) boosted with ritonavir (RTV)” NCT01475838 ↗ “Atazanavir (ATV) Powder Boosted With Ritonavir (RTV)” NCT01335698 ↗ “darunavir (DRV, administered with ritonavir [RTV])” PMID 22288567 ↗ Aug 2012 “FPV 1400mg/ritonavir (RTV) 100mg once daily” NCT00764465 ↗ “combined in a capsule with ritonavir (RTV)” NCT00004581 ↗ “3TC/ABC/amprenavir (APV)/ritonavir (RTV)” NCT00005017 ↗ “darunavir/ low-dose ritonavir (DRV/rtv)” NCT01281813 ↗ “tipranavir (TPV) and ritonavir (RTV)” NCT02251132 ↗ “atazanavir plus ritonavir (ATV+RTV)” NCT01910402 ↗ “atazanavir (ATV) + ritonavir (RTV)” NCT02469246 ↗ “ritonavir (RTV) 100 mg twice a day” NCT00381303 ↗ “ritonavir (RTV)-boosted atazanavir” NCT02246998 ↗ “ritonavir (RTV) 100mg twice daily” NCT00936793 ↗ “saquinavir (SQV), ritonavir (RTV)” NCT00039741 ↗ “Darunavir (DRV)+Ritonavir (rtv)” NCT00919854 ↗ “Ritonavir (RTV) 100 mg, 1x/day” NCT06676410 ↗ “Darunavir/Ritonavir (DRV/RTV)” NCT04630002 ↗ “ABT-378 plus ritonavir (RTV)” NCT00004583 ↗ “GW433908/ritonavir (RTV)” NCT00025727 ↗ “Ritonavir (RTV) low” NCT02249416 ↗ “Ritonavir (RTV)” NCT02256826 ↗ “ritonavir (RTV)” NCT02253875 ↗ “Ritonavir (RTV)” NCT02386098 ↗ “Ritonavir (RTV)” NCT02063360 ↗ “Ritonavir (RTV)” NCT02064842 ↗ “ritonavir (RTV)” NCT00000906 ↗ “Ritonavir (RTV)” NCT02249130 ↗ “ritonavir (RTV)” NCT00006397 ↗ “Ritonavir (RTV)” NCT02195466 ↗ |
| Known as | Viekirax | ChEMBL registry synonym — accepted as the source's own label CHEMBL163 ↗ |
| Known as | Viriton | ChEMBL registry synonym — accepted as the source's own label CHEMBL163 ↗ |
| Action | Inhibit | “other protease inhibitors (saquinavir/nelfinavir or saquinavir/ritonavir)” NCT00000892 ↗ |
| Modality | Other / unclassified | “Protease Inhibitor” NCT00000919 ↗ |
| Route | Oral | “A Phase I Trial of the Safety, Tolerance, and Pharmacokinetics of Oral Ritonavir Co-Administered With Lamivudine (3TC) and Zidovudine (ZDV) in HIV-1-Infected Pregnant Women and...” NCT00000888 ↗ |
| Target | CYP3A4 | “Ketoconazole and ritonavir are potent inhibitors of CYP3A4” NCT00770042 ↗ |